Emily Karanges
Emily Karanges
Unknown affiliation
Verified email at
Cited by
Cited by
Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011
CP Stephenson, E Karanges, IS McGregor
Australian & New Zealand Journal of Psychiatry 47 (1), 74-87, 2013
The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers
L Mellish, EA Karanges, MJ Litchfield, AL Schaffer, B Blanch, BJ Daniels, ...
BMC research notes 8 (1), 1-13, 2015
Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats
C Klein, E Karanges, A Spiro, A Wong, J Spencer, T Huynh, ...
Psychopharmacology 218, 443-457, 2011
Twenty‐five years of prescription opioid use in Australia: a whole‐of‐population analysis using pharmaceutical claims
EA Karanges, B Blanch, NA Buckley, SA Pearson
British journal of clinical pharmacology 82 (1), 255-267, 2016
Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey
EA Karanges, A Suraev, N Elias, R Manocha, IS McGregor
BMJ open 8 (7), e022101, 2018
Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009–2012: Focus on children, adolescents and prescriber specialty
EA Karanges, CP Stephenson, IS McGregor
Australian & New Zealand Journal of Psychiatry 48 (10), 917-931, 2014
Psychotropic medication use in Australia, 2007 to 2015: changes in annual incidence, prevalence and treatment exposure
J Brett, EA Karanges, B Daniels, NA Buckley, C Schneider, A Nassir, ...
Australian & New Zealand Journal of Psychiatry 51 (10), 990-999, 2017
Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion
CP Motbey, E Karanges, KM Li, S Wilkinson, AR Winstock, J Ramsay, ...
Public Library of Science 7 (9), e45473, 2012
Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents?
E Karanges, KM Li, C Motbey, PD Callaghan, A Katsifis, IS McGregor
International Journal of Neuropsychopharmacology 14 (4), 491-504, 2011
Trends in opioid utilisation in Australia, 2006‐2015: insights from multiple metrics
EA Karanges, NA Buckley, J Brett, B Blanch, M Litchfield, L Degenhardt, ...
Pharmacoepidemiology and drug safety 27 (5), 504-512, 2018
Trends in self-poisoning and psychotropic drug use in people aged 5–19 years: a population-based retrospective cohort study in Australia
R Cairns, EA Karanges, A Wong, JA Brown, J Robinson, SA Pearson, ...
BMJ open 9 (2), e026001, 2019
To what extent do data from pharmaceutical claims under‐estimate opioid analgesic utilisation in Australia?
N Gisev, SA Pearson, EA Karanges, B Larance, NA Buckley, S Larney, ...
Pharmacoepidemiology and drug safety 27 (5), 550-555, 2018
Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study
J Brett, B Daniels, EA Karanges, NA Buckley, C Schneider, A Nassir, ...
British Journal of Clinical Pharmacology 83 (11), 2581-2588, 2017
Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study
L Parker, EA Karanges, L Bero
BMJ open 9 (2), e024928, 2019
Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of “paradoxical” antidepressant …
EA Karanges, MA Kashem, R Sarker, EU Ahmed, S Ahmed, ...
Frontiers in pharmacology 4, 86, 2013
Antidepressants and adolescent brain development
E Karanges, IS McGregor
Future Neurology 6 (6), 783-808, 2011
Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study
B Behdarvand, EA Karanges, L Bero
BMJ open 9 (8), e030253, 2019
Understanding the nature and extent of pharmaceutical industry payments to nonphysician clinicians
EA Karanges, Q Grundy, L Bero
JAMA Internal Medicine 179 (10), 1430-1432, 2019
Pharmaceutical industry payments to leaders of professional medical associations in Australia:'Focus on cardiovascular disease and diabetes'
EA Karanges, N Ting, L Parker, A Fabbri, L Bero
Australian Journal of General Practice 49 (3), 151-154, 2020
Prescription opioid access patterns and factors associated with increasing number of prescribers, pharmacies, and dispensings: an observational study using pharmaceutical claims
B Blanch, L Degenhardt, NA Buckley, N Gisev, T Dobbins, EA Karanges, ...
Pain Medicine 19 (6), 1170-1183, 2018
The system can't perform the operation now. Try again later.
Articles 1–20